| 1 |
Betterle C, Furmaniak J, Sabbadin C, Scaroni C, Presotto F. Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy. J Endocrinol Invest 2023;46:643-65. [PMID: 36609775 DOI: 10.1007/s40618-022-01994-1] [Reference Citation Analysis]
|
| 2 |
Carta S, Le Duy D, Rogemond V, Derache N, Chaumont H, Fromont A, Cabasson S, Boudot de la Motte M, Honnorat J, Marignier R. Anti-Argonaute antibodies as a potential biomarker in NMOSD. J Neurol Neurosurg Psychiatry 2023:jnnp-2022-330707. [PMID: 36810322 DOI: 10.1136/jnnp-2022-330707] [Reference Citation Analysis]
|
| 3 |
Rotstein DL, Wolfson C, Carruthers R, Freedman MS, Morrow SA, Lee L, Burton JM, Nisenbaum R, Konig A, Magalhaes S, Marrie RA. A national case-control study investigating demographic and environmental factors associated with NMOSD. Mult Scler 2023;:13524585231151953. [PMID: 36803237 DOI: 10.1177/13524585231151953] [Reference Citation Analysis]
|
| 4 |
Min W, Zhang L, Wang S, Xue M, Guo C, Zhu M. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2023;70:104517. [PMID: 36708681 DOI: 10.1016/j.msard.2023.104517] [Reference Citation Analysis]
|
| 5 |
Paolilo RB, Paz JAD, Apóstolos-Pereira SL, Rimkus CM, Callegaro D, Sato DK. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arq Neuropsiquiatr 2023;81:201-11. [PMID: 36948203 DOI: 10.1055/s-0043-1761432] [Reference Citation Analysis]
|
| 6 |
Carnero Contentti E, López PA, Pettinicchi JP, Tkachuk V, Daccach Marques V, de Castillo IS, Cristiano E, Patrucco L, Caride A, Rojas JI. Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. Neurol Sci 2023. [PMID: 36645533 DOI: 10.1007/s10072-023-06611-4] [Reference Citation Analysis]
|
| 7 |
Cai L, Chen H, Shi Z, Wang X, Du Q, Zhang Y, Lang Y, Kong L, Luo W, Mou Z, Lin X, Zhou H. Non-immune system comorbidity in neuromyelitis optica spectrum disorders. J Clin Neurosci 2023;107:16-22. [PMID: 36462412 DOI: 10.1016/j.jocn.2022.11.008] [Reference Citation Analysis]
|
| 8 |
Módis LV, Aradi Z, Horváth IF, Bencze J, Papp T, Emri M, Berényi E, Bugán A, Szántó A. Central Nervous System Involvement in Primary Sjögren's Syndrome: Narrative Review of MRI Findings. Diagnostics (Basel) 2022;13. [PMID: 36611306 DOI: 10.3390/diagnostics13010014] [Reference Citation Analysis]
|
| 9 |
Alvarez MR, Gurung A, Velayndhan V, Cuascut F, Alkabie S, Freeman L, Phayal G, Kabani N, Pathiparampil J, Bhamra M, Kreps A, Koci K, Francis S, Zhaz Leon SY, Levinson J, Lezcano MR, Amarnani A, Xie S, Valsamis H, Anziska Y, Ginzler EM, McFarlane IM. Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): A retrospective analysis in two inner-city hospitals. J Neurol Sci 2022;443:120460. [PMID: 36306632 DOI: 10.1016/j.jns.2022.120460] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Sahoo D, Dash A, Dey A, Devi S. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated longitudinally extensive transverse myelitis (LETM) and primary Sjogren syndrome: a rare association. BMJ Case Rep 2022;15. [PMID: 36593613 DOI: 10.1136/bcr-2022-249915] [Reference Citation Analysis]
|
| 11 |
Ponleitner M, Rommer PS. Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis. Wien Med Wochenschr 2022. [DOI: 10.1007/s10354-022-00987-2] [Reference Citation Analysis]
|
| 12 |
Pique J, Nicolas P, Marignier R. Neuromielite ottica acuta (malattia di Devic). EMC - Neurologia 2022;22:1-11. [DOI: 10.1016/s1634-7072(22)47095-4] [Reference Citation Analysis]
|
| 13 |
Song H, Yang M, Zhou H, Li Z, Wei S. MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study. Mult Scler Relat Disord 2022;68:104248. [PMID: 36544312 DOI: 10.1016/j.msard.2022.104248] [Reference Citation Analysis]
|
| 14 |
Mireles-ramírez MA, Pacheco-moises FP, González-usigli HA, Sánchez-rosales NA, Hernández-preciado MR, Delgado-lara DL, Hernández-cruz JJ, Ortiz GG. Neuromyelitis optica spectrum disorder: Pathophysiological approach. International Journal of Neuroscience 2022. [DOI: 10.1080/00207454.2022.2153046] [Reference Citation Analysis]
|
| 15 |
Mader EC, Verdecie O, Losada V, Lovera JF. Autoimmune Myelitis and Myocarditis in a Patient With Anti-Aquaporin-4, Antinuclear, and Antiphospholipid Autoantibodies: The Neuromyelitis Optica-Systemic Lupus Erythematosus (NMO-SLE) Overlap Syndrome. Cureus 2022. [DOI: 10.7759/cureus.31334] [Reference Citation Analysis]
|
| 16 |
Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. Mult Scler J Exp Transl Clin 2022;8:20552173221128170. [PMID: 36311694 DOI: 10.1177/20552173221128170] [Reference Citation Analysis]
|
| 17 |
Zeng Y, Bai R, Zhou Y, Ren L. Neuromyelitis optica spectrum disease coexisting with subacute combined degeneration: a case report. BMC Neurol 2022;22:377. [PMID: 36195830 DOI: 10.1186/s12883-022-02870-4] [Reference Citation Analysis]
|
| 18 |
Wang X, Shi Z, Zhao Z, Chen H, Lang Y, Kong L, Lin X, Du Q, Wang J, Zhou H. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol 2022;13:959469. [DOI: 10.3389/fimmu.2022.959469] [Reference Citation Analysis]
|
| 19 |
Faisal M, Matarneh A, Alshahwani I, Al-allaf O, Al-allaf A. Neuromyelitis Optica Spectrum Disorder and Autoimmune Rheumatological Diseases: A Report of Two Cases and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.26138] [Reference Citation Analysis]
|
| 20 |
Sharma N, Sharma A, Singla N, Sharma N. Multiple autoimmune disorders in a patient with neuromyelitis optica spectrum disorder presenting with rhabdomyolysis. BMJ Case Rep 2022;15:e249102. [DOI: 10.1136/bcr-2022-249102] [Reference Citation Analysis]
|
| 21 |
Lashgari G, Solomon AJ, Kaisey M. Teaching Cases in Differential Diagnosis: Misdiagnosis of MS Perpetuated for 14 Years. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103950] [Reference Citation Analysis]
|
| 22 |
Castro-suarez S, Guevara-silva E, Osorio-marcatinco V, Alvarez-toledo K, Meza-vega M, Caparó-zamalloa C. Clinical and Paraclinical Profile of Neuromyelitis Optic Spectrum Disorder in a Peruvian Cohort. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103919] [Reference Citation Analysis]
|
| 23 |
Yang X, Li X, Lai M, Wang J, Tan S, Chan HH. Pain Symptoms in Optic Neuritis. Front Pain Res 2022;3:865032. [DOI: 10.3389/fpain.2022.865032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Zhang X, Liu X, Yu H, Deng B, Zhang Y, Chen X. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103786] [Reference Citation Analysis]
|
| 25 |
Gracia F, Ramírez D, Parajeles-vindas A, Díaz A, Díaz de la Fé A, Sánchez NER, Escobar RC, Valle LAG, Weiser R, Santos B, Candelario A, Benzadon A, Araujo P, Valderrama C, Larreategui M, Carrillo G, Gracia K, Vázquez-céspedes J, Monterrey-alvarez P, Carazo-céspedes K, Sanabria-castro A, Miranda-loria G, Balmaceda-meza A, Rivera LIP, Leal IO, Salinas LCR, Thompson A, Torres EL, Pereira DE, Zepeda C, López CA, Valse EAC, Urbina KZC, Urrutia MA, Van Sijtveld I, Armien B, Rivera VM. Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study. Neurology International 2022;14:284-93. [DOI: 10.3390/neurolint14010023] [Reference Citation Analysis]
|
| 26 |
Fukuda TG, Silva ITF, Dos Santos TSS, Filho MBP, de Abreu FF, Oliveira-Filho J. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol 2022;22:95. [PMID: 35296261 DOI: 10.1186/s12883-022-02621-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Dauby S, Dive D, Lutteri L, Andris C, Hansen I, Maquet P, Lommers E. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg 2022;122:135-44. [PMID: 34097296 DOI: 10.1007/s13760-021-01712-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 28 |
Liu J, Zhou R, Gong Y, Ding X, Huang Q, Zhang Y, Feng Y, Wang D, Zhou H, Ma Y, Zhang X, Zhou Y. A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders. J Clin Apher 2022. [PMID: 35104012 DOI: 10.1002/jca.21965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. Autoimmune Encephalitis and Related Disorders of the Nervous System 2022. [DOI: 10.1017/9781108696722.012] [Reference Citation Analysis]
|
| 30 |
Khoshgard K, Mansoory MS, Nouri H, Tavares MCH, Tomaz C, Zarei SA. Effective connectivity within the corticothalamic circuit in the neuromyelitis optica patients: A comparative study using resting-state fMRI. J Clin Neurosci 2022;97:25-31. [PMID: 35033778 DOI: 10.1016/j.jocn.2022.01.004] [Reference Citation Analysis]
|
| 31 |
李 兰. Neuromyelitisoptica Spectrum Disease with Brown-Séquard Syndrome as the Initial Presentation: A Case Report and Literature Review. ACM 2022;12:10052-10058. [DOI: 10.12677/acm.2022.12111450] [Reference Citation Analysis]
|
| 32 |
Naser Moghadasi A, Rezaeimanesh N. Microorganisms in Pathogenesis and Management of Neuromyelitis Optica Spectrum Disorder. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases 2022. [DOI: 10.1007/978-981-19-4800-8_10] [Reference Citation Analysis]
|
| 33 |
Ferilli MAN, Paparella R, Morandini I, Papetti L, Figà Talamanca L, Ruscitto C, Ursitti F, Moavero R, Sforza G, Tarantino S, Proietti Checchi M, Vigevano F, Valeriani M. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life 2021;12:19. [DOI: 10.3390/life12010019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Arévalo B, Blázquez M, Serafín V, Montero-Calle A, Calero M, Valverde A, Barderas R, Campuzano S, Yáñez-Sedeño P, Pingarrón JM. Unraveling autoimmune and neurodegenerative diseases by amperometric serological detection of antibodies against aquaporin-4. Bioelectrochemistry 2021;144:108041. [PMID: 34929532 DOI: 10.1016/j.bioelechem.2021.108041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Gorgone G, Giudice FD, David P, Franco G, Giofrè L, Grillo G, Iellamo MA, Mastrandrea C, Orlando C, Vecchio A, Galati F. Serum negative neuromyelitis optica spectrum disorder after vaxzevria vaccination: A case report. Neuroimmunology Reports 2021;1:100016. [DOI: 10.1016/j.nerep.2021.100016] [Reference Citation Analysis]
|
| 36 |
Huo L, Wang H, Yuan Y, Gao J, Liu X. Positive antithyroid antibody predicts severity of neuromyelitis optica spectrum disorder in children. Mult Scler Relat Disord 2021;57:103425. [PMID: 34906814 DOI: 10.1016/j.msard.2021.103425] [Reference Citation Analysis]
|
| 37 |
Barzegar M, Mirmosayyeb O, Ebrahimi N, Bagherieh S, Afshari-safavi A, Hosseinabadi AM, Shaygannejad V, Asgari N. COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 2021. [DOI: 10.1016/j.msard.2021.103359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Simaniv TO, Kochergin IA, Zakharova MN, Korobko DS, Zaslavskii LG, Zelenova OV, Abramov SI. [Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:96-103. [PMID: 34460164 DOI: 10.17116/jnevro202112107196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 39 |
Shahmohammadi S, Doosti R, Shahmohammadi A, Azimi A, Sahraian MA, Fattahi MR, Naser Moghadasi A. Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. Mult Scler Relat Disord 2021;56:103227. [PMID: 34536774 DOI: 10.1016/j.msard.2021.103227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 40 |
Ikeguchi R, Shimizu Y, Kondo A, Kanda N, So H, Kojima H, Kitagawa K. Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases. Neurol Neuroimmunol Neuroinflamm 2021;8:e1069. [PMID: 34429366 DOI: 10.1212/NXI.0000000000001069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 41 |
Fang GL, Fang W, Zheng Y, Zhang YX. Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment. Acta Neurol Belg 2021;121:1065-7. [PMID: 33136271 DOI: 10.1007/s13760-020-01530-z] [Reference Citation Analysis]
|
| 42 |
Mogensen FL, Delle C, Nedergaard M. The Glymphatic System (En)during Inflammation. Int J Mol Sci 2021;22:7491. [PMID: 34299111 DOI: 10.3390/ijms22147491] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 43 |
Lourenço de Medeiros C, Colares Lessa VC, Rodrigues Prata ML, Prudêncio de Lemos R, R Monfredinho A, R de Freitas G, Bittar Braune C. Neuromyelitis optica spectrum disorders and systemic lupus erythematosus: A case series from a university center. Rev Neurol (Paris) 2021:S0035-3787(21)00598-1. [PMID: 34253347 DOI: 10.1016/j.neurol.2021.03.007] [Reference Citation Analysis]
|
| 44 |
Zoghaib R, Sreij A, Maalouf N, Freiha J, Kikano R, Riachi N, Chalah MA, Ayache SS, Ahdab R. Autoimmune Brainstem Encephalitis: An Illustrative Case and a Review of the Literature. J Clin Med 2021;10:2970. [PMID: 34279454 DOI: 10.3390/jcm10132970] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 45 |
Kaufman AR, MacIntosh PW, Johnson BT. Sequential Bilateral Vision Loss in a Woman With Scalp Tenderness and Jaw Claudication. JAMA Neurol 2021;78:878-9. [PMID: 34047763 DOI: 10.1001/jamaneurol.2021.0757] [Reference Citation Analysis]
|
| 46 |
Kandemirli SG, Bathla G. Neuroimaging findings in rheumatologic disorders. J Neurol Sci 2021;427:117531. [PMID: 34130065 DOI: 10.1016/j.jns.2021.117531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 47 |
Exuzides A, Sheinson D, Sidiropoulos P, Magrini F, Gholizadeh S, Surinach A, Cook L, Meyer CS, Yeaman M. Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2021;427:117530. [PMID: 34111762 DOI: 10.1016/j.jns.2021.117530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Dehghani L, Sabbagh S, Esmaeilian-afyouni N, Shaygannejad V, Saboori M, Rezvani M, Nadeali Z, Moayednia M, Nouri H, Mortazavi Z, Safi A. High Prevalence of MMP9 −1562C/T Gene Polymorphism in an Iranian Population of Neuromyelitis Optica, A Pilot Study. Gene Reports 2021;23:101061. [DOI: 10.1016/j.genrep.2021.101061] [Reference Citation Analysis]
|
| 49 |
Asseyer S, Masuda H, Mori M, Bellmann-Strobl J, Ruprecht K, Siebert N, Cooper G, Chien C, Duchow A, Schließeit J, Liu J, Sugimoto K, Uzawa A, Ohtani R, Paul F, Brandt AU, Kuwabara S, Zimmermann HG. AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2021;7:20552173211006862. [PMID: 34017610 DOI: 10.1177/20552173211006862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Mittal A, Baig IF, Merchant AG, Chen JJ, Choi JJ, Goldberg A, Adesina OO. Sjögren Disease and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. J Neuroophthalmol 2021;41:e48-50. [PMID: 32235221 DOI: 10.1097/WNO.0000000000000945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 51 |
Ha Y, Lee YJ. Pharmacological Management of Sjögren’s Syndrome. Sjögren's Syndrome and Oral Health 2021. [DOI: 10.1007/978-3-030-72029-2_11] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 52 |
Barzegar M, Mirmosayyeb O, Nehzat N, Vaheb S, Shaygannejad V, Asgari N. Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. Mult Scler Relat Disord 2021;48:102685. [PMID: 33321342 DOI: 10.1016/j.msard.2020.102685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 53 |
Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S; PREVENT Study Group. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord 2021;47:102641. [PMID: 33310418 DOI: 10.1016/j.msard.2020.102641] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 54 |
Eguchi H, Takeshige H, Nakajima S, Kanou M, Nakajima A, Fuse A, Fukae J, Miwa H, Shimo Y. Herpes Zoster Radiculomyelitis With Aquaporin-4 Antibodies: A Case Report and Literature Review. Front Neurol 2020;11:585303. [PMID: 33329330 DOI: 10.3389/fneur.2020.585303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 55 |
Janssen M, Bruijstens AL, van Langelaar J, Wong Y, Wierenga-Wolf AF, Melief MJ, Rijvers L, van Pelt ED, Smolders J, Wokke BH, van Luijn MM. Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses. Brain Commun 2020;2:fcaa197. [PMID: 33305266 DOI: 10.1093/braincomms/fcaa197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Elnady B, Fathy SM, Elkhouly T, Ganeb S. Neuromyelitis optica spectrum standstill in rheumatic systemic autoimmune diseases. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00018-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 57 |
Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, Shi FD. Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study. Lancet Reg Health West Pac 2020;2:100021. [PMID: 34327375 DOI: 10.1016/j.lanwpc.2020.100021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 58 |
Akaishi T, Takeshita T, Himori N, Takahashi T, Misu T, Ogawa R, Kaneko K, Fujimori J, Abe M, Ishii T, Fujihara K, Aoki M, Nakazawa T, Nakashima I. Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. Front Neurol 2020;11:932. [PMID: 33013632 DOI: 10.3389/fneur.2020.00932] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 59 |
Bates M, Chisholm J, Miller E, Avasarala J, Guduru Z. Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis. Multiple Sclerosis and Related Disorders 2020;44:102205. [DOI: 10.1016/j.msard.2020.102205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 60 |
Topuzova MP, Bisaga GN, Alekseeva TM, Isabekova PS, Сhaykovskaya AD, Panina EB, Pavlova TA, Ternovykh IK. [Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:97-106. [PMID: 32844638 DOI: 10.17116/jnevro202012007297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 61 |
Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol 2020;11:778. [PMID: 33473247 DOI: 10.3389/fneur.2020.00778] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 62 |
Krasnov VS, Makshakov GS, Kalinin IV, Laskova KK, Shumilina MV, Evdoshenko EP, Totolyan NA. [Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:102-8. [PMID: 32790983 DOI: 10.17116/jnevro2020120071102] [Reference Citation Analysis]
|
| 63 |
Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020;7:1477-87. [PMID: 32767531 DOI: 10.1002/acn3.51136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 64 |
Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020;19:391-401. [PMID: 32333897 DOI: 10.1016/S1474-4422(20)30070-3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 89] [Article Influence: 37.7] [Reference Citation Analysis]
|
| 65 |
Rezaei SJ, Vogel AC, Gazdag B, Alakel N, Kumar AR, Mateen FJ. Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists. J Neuroimmunol 2020;346:577320. [PMID: 32682142 DOI: 10.1016/j.jneuroim.2020.577320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Ling J, Micieli JA. Recurrent MOG-IgG Optic Neuritis Initially Attributed to Sjögren's Syndrome. Can J Neurol Sci 2020;47:864-5. [PMID: 32522294 DOI: 10.1017/cjn.2020.120] [Reference Citation Analysis]
|
| 67 |
Rocca MA, Cacciaguerra L, Filippi M. Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. Expert Review of Neurotherapeutics 2020;20:601-18. [DOI: 10.1080/14737175.2020.1764352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 68 |
Hung SC. Imaging of Neuromyelitis Optica Spectrum Disorders. Semin Ultrasound CT MR 2020;41:319-31. [PMID: 32448488 DOI: 10.1053/j.sult.2020.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Castro-Suarez S, Guevara-Silva E, Caparó-Zamalloa C, Cortez J, Meza-Vega M. Neuromyelitis optica in patients with myasthenia gravis: Two case-reports. Mult Scler Relat Disord 2020;43:102173. [PMID: 32442888 DOI: 10.1016/j.msard.2020.102173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Fujii T, Yamasaki R, Miyachi Y, Nagata S, Maimaitijiang G, Nakamura Y, Shinoda K, Matsushita T, Isobe N, Kira JI. Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. J Neurol Sci 2020;409:116619. [PMID: 31835211 DOI: 10.1016/j.jns.2019.116619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 71 |
Naser Moghadasi A. Environmental and genetic risk factors in the development of neuromyelitis optica. Expert Review of Ophthalmology 2020;15:1-9. [DOI: 10.1080/17469899.2020.1723416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 72 |
Bukhari W, Clarke L, O'Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA. The clinical profile of NMOSD in Australia and New Zealand. J Neurol 2020;267:1431-43. [PMID: 32006158 DOI: 10.1007/s00415-020-09716-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 73 |
Filippi M, Rocca MA. Neuromyelitis Optica Spectrum Disorders. White Matter Diseases 2020. [DOI: 10.1007/978-3-030-38621-4_3] [Reference Citation Analysis]
|
| 74 |
Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, Shapiro L. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord 2019;39:101906. [PMID: 31887565 DOI: 10.1016/j.msard.2019.101906] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 75 |
Thabah MM, D S, Pranov R, Moulitej MMV, Ramesh A, Kadhiravan T. Neuromyelitis optica spectrum disorder and systemic lupus erythematosus. Lupus 2019;28:1722-6. [PMID: 31722604 DOI: 10.1177/0961203319888692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 76 |
Williams JN, Speyer CB, Kreps DJ, Kimbrough DJ, Costenbader K, Bhattacharyya S. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus 2019;28:1656-62. [PMID: 31679449 DOI: 10.1177/0961203319886103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Oliveira R, Oliveira S. Letter to the Editor - Late-onset neuromyelitis optica associated with cryptogenic organizing pneumonia. Multiple Sclerosis and Related Disorders 2019;36:101398. [DOI: 10.1016/j.msard.2019.101398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 78 |
Martín-nares E, Hernandez-molina G, Fragoso-loyo H. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus 2019;28:1302-11. [DOI: 10.1177/0961203319877255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 79 |
Abel A, McClelland C, Lee MS. Critical review: Typical and atypical optic neuritis. Surv Ophthalmol 2019;64:770-9. [PMID: 31229520 DOI: 10.1016/j.survophthal.2019.06.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 9.8] [Reference Citation Analysis]
|
